Fidelity Enhanced Income W Acc
|AstraZeneca PLC||5.39 %|
|BP PLC||5.07 %|
|Royal Dutch Shell PLC Class A||4.96 %|
|HSBC Holdings PLC||4.94 %|
|GlaxoSmithKline PLC||4.15 %|
|Unilever PLC||3.56 %|
|Legal & General Group PLC||3.50 %|
|Diageo PLC||3.48 %|
|British American Tobacco PLC||3.32 %|
|Reckitt Benckiser Group PLC||3.27 %|
|United Kingdom||98.58 %|
|Financial Services||25.95 %|
|Consumer Defensive||16.99 %|
|Consumer Cyclical||9.97 %|
Michael Clark joined Fidelity International in 2002 as an Equity Research Analyst. From 2002 to 2007 he covered a variety of sectors including oil services, construction and housebuilding, automotive and mining. Michael became a Portfolio Manager in 2007. Prior to joining Fidelity, Michael was an equity analyst for JP Morgan, Enskilda and Morgan Grenfell. Through these positions, he covered the engineering, consumer goods, pharmaceuticals and industrial services sectors, and now has a total of 22 year’s experience. Michael holds an MA in Modern Languages from Cambridge University.
Data provided by Morningstar.
The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.
This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.
You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.